

Review

The Role of Skin Barrier in the Pathogenesis of Food Allergy

Neema Izadi ^{1,†}, Minnelly Luu ^{2,†}, Peck Y. Ong ³ and Jonathan S. Tam ^{3,*}

¹ Department of Pediatrics, Children's Hospital Los Angeles, Los Angeles, CA 90027, USA; E-Mail: nizadi@chla.usc.edu

² Department of Dermatology, Keck School of Medicine, University of Southern California; Los Angeles, CA 90033, USA; E-mail: mluu@chla.usc.edu

³ Division of Clinical Immunology and Allergy, Department of Pediatrics, Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California; Los Angeles, CA 90027, USA; E-Mail: pyong@chla.usc.edu

† These authors contributed equally to this work.

* Author to whom correspondence should be addressed; E-Mail: jstam@chla.usc.edu; Tel.: +1-323-361-2501; Fax: +1-323-361-1191.

Academic Editor: Jonathan M. Spergel

Received: 01 June 2015 / Accepted: 25 August 2015 / Published: 02 September 2015

Abstract: Food allergy is a serious public health problem with an increasing prevalence. Current management is limited to food avoidance and emergency treatment. Research into the pathogenesis of food allergy has helped to shape our understanding of how patients become sensitized to an allergen. Classically, food sensitization was thought to occur through the gastrointestinal tract, but alternative routes of sensitization are being explored, specifically through the skin. Damaged skin barrier may play a crucial role in the development of food sensitization. Better understanding of how patients initially become sensitized may help lead to the development of a safe and effective treatment for food allergies or better prevention strategies.

Keywords: food allergy; skin barrier; allergic sensitization; filaggrin

1. Introduction

Food allergy represents a serious public health problem, with recent studies showing an increased prevalence in both North America and the United Kingdom. Although an exact figure is difficult to obtain, current estimates show that food allergy affects approximately 6%–8% of young children and 3%–4% of adults in the United States [1]. The increase in prevalence has led to an unsurprising increase in anaphylaxis and hospitalizations [2,3]. Unfortunately, current therapeutic options are limited to avoidance of the culprit allergen and injectable epinephrine in case of accidental exposure.

Most individuals with food allergy are otherwise in good health; however, the unpredictable and episodic nature of acute and potentially life-threatening food-allergic reactions may lead to significant distress for affected children and their parents or caregivers [4,5]. Furthermore, food allergy results in significant medical costs for the US health care system, especially in families with a food-allergic child [6]. Considering the rising prevalence, negative effects on quality of life, and financial burdens of food allergy, there is significant interest in understanding the mechanisms behind food allergy to help guide and develop therapies.

Recent research has focused on modifying risk of developing food allergy through improved understanding of factors, such as timing and route of exposure that lead to allergic sensitization *versus* tolerance. Sensitization refers to the development of an immune state in which antigen exposure leads to an immune response with the potential for hypersensitivity with re-exposure. By contrast, tolerance refers to the immune state in which no significant immune response is mounted upon re-exposure [7]. Food allergy must begin with an initial sensitization event to the food protein; however, the route and timing by which this sensitization occurs currently remain unclear. Classically, food sensitization was thought to occur primarily through the gastrointestinal tract [8], but alternative routes of sensitization are currently being explored, specifically through the skin. Here we review the mechanisms of allergic sensitization to foods and their implications for the future directions of food allergy prevention and treatment.

2. Oral Tolerance and Allergic Sensitization through the Gut

Despite the extent of foreign protein exposure, relatively few patients have food allergies due to the development of oral tolerance. Oral tolerance is the state of unresponsiveness to everyday ingestion of harmless antigens and is produced by the inherent mechanical process of digestion as well as specific mechanisms of immune suppression [9]. Disturbances at various steps along the pathway of oral tolerance result in food sensitization and food allergy.

Oral tolerance begins with the basic process of digestion and absorption, which prevents most food antigens from presentation to the immune system. Food proteins that enter the gut are digested by proteases and absorbed as a mixture of free amino acids and peptides. Proteins that escape digestion predominantly pass through the gut without incident due to the intact mucosal barrier of the gastrointestinal tract and partial degradation by gastric acid [10–12]. Infants secrete less stomach acid and have less pancreatic enzyme output compared to adults [13]. Combined with a somewhat increased intestinal permeability [14,15], this increases the chances of intact allergen crossing the epithelial border and the risk for sensitization and allergy in infants. Interestingly, clinical observations and

murine models indicate that treatment with antacid medications may also increase the risk of sensitization to ingested foods [16].

For proteins that bypass the protective mechanisms of digestion, oral tolerance may still occur due to mechanisms of unresponsiveness mediated by the gastrointestinal immune system. Active sampling of intestinal antigen helps to regulate immune responses and to ensure intestinal homeostasis. Gut sampling of food proteins can occur through multiple mechanisms including intestinal epithelial cells (IECs), microfold cells (M cells), or directly by macrophages and dendritic cells (DCs). IECs and M cells both release factors important for the development of oral tolerance. IECs can package and export food antigens to be sampled by professional antigen presenting cells (APCs) in the *lamina propria* [17,18], or act as nonprofessional APCs and present antigen themselves directly to T cells [19,20]. IEC involvement results in tolerance due to unique factors that dampen the immune response and promote gut homeostasis [21].

The relationship between allergic response and other types of immune regulation is dependent on T cell control. Specific T helper (Th) subsets dictate cytokine production and the regulation of these responses. Classically, Th2 inflammatory responses typify the allergic response involving immunoglobulin (Ig)E production and eosinophilic infiltration as a result of the actions of interleukin (IL)-4, IL-5, and IL-13 [22]. Another subset of T cells characterized by high levels of CD25 expression (IL-2 receptor (R) α chain) have been identified as regulatory T cell (Tregs), because they were found to suppress the function of other T cells when present in the same site [23]. These CD4+CD25+ Tregs are pivotal in oral tolerance and active immune regulation [24]. Interactions between different aspects of the mucosal immune system with Tregs make up a large portion of the current understanding for mechanisms in oral tolerance.

For example, IECs have also been shown to aid in the generation of tolerogenic dendritic cells and subsequently Tregs [25]. Moreover, classic APCs like macrophages and DCs in the gut lead to immune suppression mainly through specific Treg differentiation and production of anti-inflammatory cytokines like IL-10 [26,27]. Macrophages and DCs can also directly sample antigen by sending out protrusions between epithelial cells [28,29], and then migrate to mesenteric lymph nodes (MLNs) in a C-C chemokine receptor (CCR)7 dependent manner [26,30]. CD11c⁺CD103⁺CX3CR1⁻ DCs decrease sensitization through Flt3 (FMS-like tyrosine kinase-3) ligand mediated expansion [31], and release transforming growth factor (TGF)- β , and retinoic acid leading to expansion of Foxp3+ (forkhead box P3+) T regulatory cells [24,31–36].

M Cells line the apices of Peyer's patches and specialize in the uptake of particulate antigens, delivering them to APCs. They lack a brush border and have a deeply invaginated surface for easy uptake of antigen to be presented to APCs in the membrane pocket or in local gut-associated lymphoid tissue (GALT) for TGF- β mediated IgA switching and differentiation of Tregs [37–41]. IgA has been shown to play an adjunct role to prevent sensitization through binding of antigen to prevent systemic absorption [24,42]. Mice deficient in the ability to secrete IgA and IgM were much more sensitive to IgG-mediated anaphylaxis [43]; however, mice could still be orally tolerized despite low levels of fecal IgA production suggesting IgA is helpful, but not necessary to oral tolerance [44].

Immunological as well as genetic evidence support Tregs role in oral tolerance. Children with a history of milk allergy who went on to develop tolerance had higher frequency of CD4+CD25+ Tregs compared to those who maintained clinically active allergy [45]. Further, children who recently

developed natural tolerance to their egg or peanut allergy showed higher number of Tregs compared to allergic or non-allergic control patients [46], further suggesting an important role for regulatory T cell subsets in the acquisition of natural tolerance. Mutations in the *FoxP3* gene result in absent or abnormal Tregs and lead to the syndrome IPEX (immune dysregulation, polyendocrinopathy, X-linked) [47,48]. These patients with IPEX develop food allergies and eczema demonstrating a failure of tolerance. Murine studies show that depletion of Tregs alone leads to loss of oral tolerance [26,32]. Moreover, in mice Tregs are sufficient to diminish the allergy response [49], likely through secretion of the inhibitory molecules such as glucocorticoid-induced TNFR (Tumor necrosis factor receptor) family related gene (GITR), CTLA4 (cytotoxic T-lymphocyte-associated protein 4) [50], TGF- β , and IL-10 [51] and the downregulation of pro-effector T cell cytokines such as IL-2 [52–55]

3. Allergic Sensitization through the Skin

Several clinical observations support the existence of sensitization routes other than the gut. For example, allergic reactions to foods have been noted to occur without prior ingestion exposure [56,57], and in general, oral exposure to foods are limited in infancy and lead to tolerance [58,59]. While the potential role for exposure in utero or through breast milk has been proposed, there is some conflicting evidence that suggests that these exposures may more likely induce tolerance rather than sensitization [60–62]. Taken together, this evidence suggests that another route other than perinatal and oral may be important to the development of food allergies.

Recently, the skin has garnered significant interest as a potential important route for allergic sensitization. Epidemiologic data suggests that sensitization to peanut protein can occur in children via exposure of inflamed skin to peanut oils [63]. In a study by Lack *et al.*, the risk of allergic sensitization to peanut in children with atopic dermatitis (AD) was not associated with maternal peanut ingestion during pregnancy or lactation; however development of peanut allergy was significantly increased in those infants using skin creams containing peanut oil [63].

Furthermore, a study comparing children with peanut allergy, children with egg allergy (high risk control group), and children without allergy found a dose-dependent relationship between household peanut consumption and the development of peanut allergy [64]. There was no difference in peanut consumption between the three groups of children suggesting that increased household consumption led to increased allergy to peanut via another route, possibly exposure to peanut dust [64]. Household peanut dust is known to directly correlate with household consumption, and in fact multivariate regression analysis has shown household peanut dust to correlate most closely with peanut protein levels in the infant's environment (crib, play area, sheets, *etc.*) [65,66]. Moreover, a dose dependent increase in sensitization with peanut dust levels was observed in patients with atopic dermatitis and fillagrin loss-of-function mutations [67,68]. This further suggests a transdermal route of sensitization given the impaired skin barrier in these populations.

Although peanut dust exposure can occur via the airway, current evidence supports the skin as a more likely route for sensitization. Higher levels of skin homing receptors on peanut-reactive T cells suggest that the initial peanut sensitization event occurs in the skin. Studies in patients with peanut allergy have shown T cells with high expression of skin homing receptor CLA (cutaneous leucocyte-associated antigen receptor) in the serum [69]. Additionally peanut component Ara h1

reactive T cells in the serum of peanut allergic individuals expressed high levels of CCR4, another skin homing receptor [70].

Like the mucosal immune system and gastrointestinal tract, the skin barrier plays a critical role in host defense against microbial invasion and allergen exposure. The skin epidermis is a highly complex, dynamic, self-renewing barrier against the external environment. The *stratum corneum* (SC), the outermost layer of the epidermis, is a sturdy barrier comprised of crossed-linked matrix containing lipids and proteins produced by keratinocytes, which minimize both water loss and protect from microbial or allergen penetration. Tight junctions (TJs) act as an intercellular sealing apparatus responsible for the compartmentalization of extracellular environments [71]. The TJ barrier acts as a divider between two liquid compartments. However, TJs are not just physical barriers. In fact, they exhibit ion and size selectivity that allows for dynamic regulation of substances crossing between compartments.

Filaggrin (FLG) is an important protein of the skin and serves several crucial functions to maintain the integrity of the skin barrier. Filaggrin is a highly insoluble 37-kD protein that derives from a more abundant 400 kD proprotein, profilaggrin [72]. Profilaggrin is the main component of keratohyalin granules in the *stratum granulosum* (SG) of the epidermis. During terminal differentiation of the keratinocyte, proteases process profilaggrin into monomers [73] that function to align and assemble keratin intermediate filaments into macrofibrils, thus providing integrity and strength to the SC [74–76].

Filaggrin is also involved in the crucial natural moisture and acidic environment of the skin. Filaggrin monomers are broken down into amino acids and other derivatives that readily attract moisture to form natural moisturizing factor (NMF) [77,78], hygroscopic compounds important for SC hydration. FLG and its derivatives, particularly urocanic acid, play important roles in maintaining an acidic skin pH. This acidic pH environment modulates serine proteases [79], which effect lipid assembly and SC organization both *in vitro* [78,80–82] and in murine models [83–85]. The acidic environment maintained by filaggrin has also been shown to provide a protective state against bacterial colonization, specifically *Staphylococcus aureus*. Key proteins important for *S. aureus* colonization, such as iron-regulated surface determinant A, are downregulated by the acidic environment provided by filaggrin in intact skin [86]. In addition, the skin barrier defect in AD leads to increased binding protein secretion and more efficient colonization by *S. aureus* [86]. Not surprisingly, over 90% of patients with AD are colonized with *S. aureus* compared to only 5% in healthy individuals [87]. Preventing *S. aureus* growth is important as increased colonization can lead to increased sensitization through bacterial superantigens and an overall heightened immune state from *S. aureus* proteins [87,88].

The importance of filaggrin deficiency in allergic sensitization has been shown in several murine studies using the filaggrin loss of function mutation (*FLG*) flaky tail (ft/ft) mouse. In a key study of these flaky tail mice, ovalbumin (OVA) was applied to the skin to elicit inflammatory infiltrates and enhanced allergen priming [89]. While the normal mice did not develop any specific IgE response, the flaky tail mice showed elevated OVA-specific IgE without any additional adjuvant or abrasion of the skin. However, transmembrane protein79 (*Tmeme79/matt*) gene, rather than *FLG*, was later proven to be responsible for the spontaneous development of dermatitis—in the flaky tail mouse model [90,91].

Tmem79/matt gene encodes for lamella granular proteins, which are responsible for processing filaggrin, lipids, proteases and antimicrobial peptides.

FLG has been associated with increased food allergy and several diseases with known barrier defects such as *ichthyosis vulgaris* and AD [80]. Depending on the study, *FLG* has been found in high percentages of up to 56% in these conditions [92]. In food allergy, the impaired skin barrier resulting from defects in filaggrin expression has been hypothesized as a gateway for food allergens and as a way to avoid the oral tolerance pathways of the gut mucosa [93]. This may also explain the connection between early severe atopic dermatitis and food allergy. In fact, *FLG* loss of function has been directly associated with human food allergy. An analysis of 71 peanut allergic patients from Europe as compared to 1000 non-allergic patients showed a strong and statistically significant connection between the occurrence of the allergy and *FLG*. This risk was further replicated in analysis of the results from 390 Canadian patients [94]. A large 18-year birth cohort showed a strong association between filaggrin loss-of-function mutation and food allergy only when patients also developed eczema [95]. This suggests that increased food allergy in filaggrin deficiency is mainly due to the barrier dysfunction of eczema, rather than a direct interaction between filaggrin and the immune system. In another cohort, a similar indirect effect of filaggrin loss-of-function was demonstrated for all ages except in the first year of life [96]. This further suggests the primary role of filaggrin in barrier integrity given that the barrier defects of eczema can precede the clinical diagnosis in infancy [97].

Disruptions of barrier function other than filaggrin deficiency are generally required for epicutaneous sensitization. In most mouse models of epicutaneous sensitization, the SC needs to be mechanically impaired by tape-stripping, patch dressing, or treatment with adjuvant [98,99]. Mouse models of skin sensitization with adjuvant or barrier disruption have shown potent Th-2 response through high IL-4 and IgE in response to peanut sensitization [100], and a long-lasting dose dependent IgE response to hazelnut sensitization [101,102]. Furthermore, a murine study comparing all forms of sensitization with adjuvant (intra-gastric, cutaneous, intranasal, and sublingual) found maximal sensitization to the cutaneous route of exposure [103]. The one notable exception to the requirement of barrier disruption appears to be for peanut. In mice, peanut skin exposure alone without any skin stripping promotes a Th2-dependent sensitization to peanut allergens [104]. This special adjuvant activity to peanuts, not only shows the unique nature of peanut allergy, but also underscores the skin as a key site of sensitization.

Skin sensitization, although not as widely studied as the gut, most likely involves thymic stromal lymphopoietin (TSLP). Many studies in the skin suggest TSLP plays a significant role in sensitization. TSLP is an IL-7 like type I cytokine predominantly expressed by epithelial cells [21]. *In vitro* evidence suggests increased expression in the lesional skin of AD patients [105], and TSLP has been shown to potentiate DCs to preferentially differentiate naïve T cells to Th2 cells [106,107]. Similarly, skin specific overexpression of TSLP in a transgenic mouse model demonstrated a dramatic Th2 inflammatory response including increased Th2 CD4⁺ T cells and elevated IgE [108]. TSLP has also been shown to effect DCs migration to the skin. DCs acquired skin specific migration signals through a TSLP-induced CCR7 and C-X-C chemokine receptor (CXCR)4-dependant pathway leading to contact hypersensitivity in mice [109,110], further demonstrating TSLP role in skin sensitization.

Another important downstream mediator of skin sensitization is OX40L and IL-33. As in the gastrointestinal mucosa, TSLP-activated DCs express OX40L [107], a member of the TNF

superfamily implicated in the communication between B cells and T cells [111]. OX40L has been shown to be necessary for the Th2 inflammatory response in mouse models of oral sensitization [112], and recent studies suggest OX40L is also important in skin sensitization mainly through IL-33. In peanut sensitization, OX40L is upregulated in an IL-33 dependent manner [113], and skin-selective IL-33 alone leads to significantly increased Th2-mediated AD-like inflammation in mice [114]. IL-33 has been shown to exacerbate anaphylaxis through mast cell degranulation [115,116], and blocking IL-33 prevents anaphylaxis in cutaneously sensitized mice [117]. Thus, IL-33 and OX40L may represent potential targets for cutaneous sensitization to food antigens in future therapies.

Basophils have recently been implicated as important mediator of skin sensitization. Recent studies have demonstrated that TSLP can drive basophil-dependent Th2 cytokine response [118,119], IgE increase, and accumulation of mast cells in the intestine promoting food allergy [120]. Furthermore, mice epicutaneously sensitized to OVA were protected from oral challenge and did not produce OVA-specific IgE in basophil-depleted or TSLP-receptor-deficient mice, further highlighting the role of basophils and TSLP in skin sensitization [117]. Basophils likely mediate their Th2 effect either as non-professional APCs by presenting antigen themselves [118] or cooperatively with DCs to mediate the downstream production of IL-4 [121,122], leading to increased anaphylaxis, marked mastocytosis, and less tolerance in murine studies [123,124].

The phenomenon of skin sensitization leading to an oral allergic response has been recently coined the “dual-allergen-exposure” hypothesis [125]. This hypothesis further proposes that exposure to food antigens through the skin is more likely to lead to allergy compared to early oral consumption, which is more likely to lead to tolerance. The previously discussed tendency of the gut mucosa to elicit tolerance compared to the more sensitizing mechanisms of the skin makes a strong case for this hypothesis. Furthermore, what ultimately determines food allergy is likely a combination of both skin and gut exposure to a particular food antigen with a higher tendency toward sensitization if the first exposure is through the skin. Given the difficulty of eliminating food allergy once it is established, primary prevention based on this hypothesis becomes important.

Clinical evidence demonstrating the validity of the dual-allergen hypothesis led the American Academy of Pediatrics in 2008 to shift its position on food exposure in infancy to favor early oral exposure to allergic foods, thus reversing prior recommendations of waiting past infancy for children at risk for atopic disease [61]. For many years, exclusive breastfeeding and careful elimination diets were considered the best methods for prevention of food allergy. However, introducing previously avoided foods such as cow’s milk, egg, fish, wheat, sesame and peanut has been recently studied in a large cohort of exclusively breastfed infants with no deleterious effects or disruptions in breastfeeding [126]. This lack of evidence and a continued rise in food allergy prevalence suggested that these preventative methods were ineffective. More recent evidence argues that early oral exposure to establish oral tolerance might be a more prudent approach [125,127]. Evidence supporting the role of early exposure in decreasing food allergy has been well demonstrated with peanut allergy [128]. In fact, a recent randomized study done by the Learning Early about Peanut Allergy group demonstrated a dramatic difference in peanut allergy prevalence of 17.2% in the avoidance group compared to only 3.2% in the consumption group [59].

4. Future Directions for the Treatment of Food Allergy

The current standard of food avoidance for prevention of food allergy is difficult given frequent accidental exposures and the potential deleterious effects on quality of life. However, new desensitization therapies are currently on the rise. As stated previously, the present standard of care is strict dietary avoidance as there is currently no approved treatment or disease-modifying therapy for the routine management of patients with food allergies. Food avoidance strategies are not only difficult but they also pose the risk of malnutrition [129], poor growth [130], accidental exposure, and decreased quality of life in children [131–133]. The most promising therapy in development for the effective treatment of food allergy is desensitization through controlled antigen exposure involving oral or sublingual immunotherapy (OIT and SLIT) [134,135]. Both SLIT (peanut, milk, hazelnut, fruit, peach), and OIT (peanut, milk, egg) have been shown to be efficacious in reducing food allergy through several studies [135,136]. SLIT is considered safer as smaller quantities are used in the mouth and many important allergen epitopes are digested in the stomach, while OIT can use higher doses making it more efficacious but also more prone to adverse reactions. This comparison between SLIT and OIT has been shown both retrospectively with peanut allergy [137] and in a recent open-label randomized human study of milk tolerance, where OIT showed significantly more desensitization but at the cost of more systemic side effects [138]. Given the higher rate of desensitization OIT is generally considered the preferred route of immunotherapy [135].

The exact mechanism of desensitization from immunotherapy is not completely understood but changes in the levels of immunoglobulins and FoxP3 expression (Tregs) have been implicated. Several potential immune mechanisms have been proposed including: decreasing levels of specific IgE, increased specific IgG, decreased reactivity of basophils and mast cells, and increased Tregs [139,140]. In addition, a recent study using patients with peanut allergy found increased specific Tregs activity and hypomethylation of FoxP3 sites in immune tolerant individuals when compared to non-tolerant; however, no significant difference was found in peanut specific IgE or basophil activation [141]. Thus, OIT induced epigenetic modifications, mainly hypomethylation, may lead to increased FoxP3 activity and be pro-tolerogenic.

Since skin is a likely site of sensitization, it seemed natural that it could be used as a point of treatment. Epicutaneous immunotherapy (EPIT) utilizes the placement of a patch of soluble allergen directly on intact skin. This approach is not only noninvasive but has been shown to have very minimal side effects [142]. The efficacy of EPIT was first established in mouse models. Mice sensitized to peanut who were given EPIT showed significantly reduced Th2 cytokines, reduced IgE response, increased specific IgG, and increased FoxP3 mRNA after oral challenge when compared to placebo mice [143]. Further evidence of EPIT efficacy was found with pollen, house dust mite, and OVA exposure; however, when compared to traditional subcutaneous immunotherapy (SCIT) there was no significant difference in decreasing the IgE/IgG ratio [144]. Similar equivalence between EPIT and SCIT was also observed in mice again sensitized to peanut antigen [145].

Mouse models have also helped us understand the possible mechanism of desensitization through intact skin. One study of mice using OVA EPIT demonstrated that prolonged application leads to antigen capture by DCs in the SC with transportation to draining lymph nodes [146]. Furthermore, repeated exposure to OVA down-modulated specific and systemic responses with an associated

induction of Tregs [146]. In a recent study, still in progress, EPIT significantly decreased the Th2 immune response and increased FoxP3⁺ Tregs [147]. Two other very recent studies, also works in progress, have shown increased gut homing receptors CXCR3, CCR6, CCR8 in response to EPIT but not SLIT or OIT [148], and increased CCR6 and CCR9 with antigen-specific latency-associated peptide⁺, FoxP3⁺ that was absent in OIT-treated mice [149]. This increased gut homing mediated by EPIT may represent a desensitization advantage over other forms of therapy given the gut mucosa's predilection toward tolerance.

Preliminary evidence of EPIT in human trials has shown some promise. The largest human study to date is a single-centered, placebo-controlled, double-blind trial of grass pollen sensitization where 37 adult patients were found to have decreased nasal provocation tests compared to placebo by the 2nd year of EPIT and significantly decreased skin prick response with only 10% having mild local reactions requiring antihistamines [150]. More recently, a bicenter, double-blind placebo-controlled (DBPC) study of children with oral challenge positive milk allergy showed good tolerability but showed little change in food challenge after three months, although similar oral immunotherapy studies have shown that benefits become more apparent after more than one year [142]. However, given the acceptable safety profile, a comprehensive plan to develop EPIT for peanut allergy by DBV Technologies has made great strides. After completing a DBPC phase I safety trial with only mild adverse reactions, a subsequent DBPC phase IIa trial showed promising results with up to 67% desensitization response for 54 children with severe peanut allergy at 18 months and four subjects even tolerating doses of up to 3.3 to 8 peanuts [151]. A follow up DBPC phase IIb dose-finding trial running in 22 centers in the United States and Europe reached its primary endpoint using Viaskin brand Peanut at a 250 microgram dose where 53.6% of children responded to treatment compared to 19.4% in the placebo group at 12 months with increased peanut-specific IgG by over 19 times, and IgE increasing at first but then decreasing toward initial levels [152]. This study demonstrates the potential of EPIT and hopefully increased focus on EPIT for other allergies will lead to more well-established convenient routes of desensitization in the future. Lastly, recent studies have shown that skin barrier therapy may prevent *atopic dermatitis* [153,154]. Whether such therapy may lead to the prevention of food allergy in atopic dermatitis patients remains to be an area of interest for future investigations.

5. Summary

Food allergy is a serious public health concern with the most established therapies limited to food avoidance and emergency treatment. To develop better therapies, it is important to understand how the route of exposure may determine sensitization vs. tolerance. The damaged skin barrier may play a crucial role in the development of food sensitization. As we learn more about the process of sensitization through the skin, it seems like a natural extension to use it as a mode of treatment. Both murine and human EPIT studies have shown promise, but more research is needed to establish both safety and efficacy. But perhaps more importantly, as more is learned about the origins of sensitization, there might one day be a way of preventing the allergy altogether.

Author Contributions

All authors contributed extensively to the work presented in this paper.

Conflicts of Interest

The authors declare no conflict of interest.

References

1. Sicherer, S.H. Epidemiology of food allergy. *J. Allergy Clin. Immunol.* **2011**, *127*, 594–602.
2. Rudders, S.A.; Arias, S.A.; Camargo, C.A. Trends in hospitalizations for food-induced anaphylaxis in US children, 2000–2009. *J. Allergy Clin. Immunol.* **2014**, *134*, 960–962.
3. Turner, P.J.; Gowland, M.H.; Sharma, V.; Ierodiakonou, D.; Harper, N.; Garcez, T.; Pumphrey, R.; Boyle, R.J. Increase in anaphylaxis-related hospitalizations but no increase in fatalities: An analysis of United Kingdom national anaphylaxis data, 1992–2012. *J. Allergy Clin. Immunol.* **2015**, *135*, 956–963.
4. Cummings, A.; Knibb, R.C.; King, R.; Lucas, J. The psychosocial impact of food allergy and food hypersensitivity in children, adolescents and their families: A review. *Allergy* **2010**, *65*, 933–945.
5. Lieberman, J.A.; Sicherer, S.H. Quality of life in food allergy. *Curr. Opin. Allergy Clin. Immunol.* **2011**, *11*, 236–242.
6. Gupta, R.; Holdford, D.; Bilaver, L.; Dyer, A.; Holl, J.L.; Meltzer, D. The economic impact of childhood food allergy in the United States. *JAMA Pediatr.* **2013**, *167*, 1026–1031.
7. Vickery, B.P.; Scurlock, A.M.; Jones, S.M.; Burks, A.W. Mechanisms of immune tolerance relevant to food allergy. *J. Allergy Clin. Immunol.* **2011**, *127*, 576–584.
8. Helm, R.M.; Burks, A.W. Mechanisms of food allergy. *Curr. Opin. Immunol.* **2000**, *12*, 647–653.
9. Chehade, M.; Mayer, L. Oral tolerance and its relation to food hypersensitivities. *J. Allergy Clin. Immunol.* **2005**, *115*, 3–12.
10. Michael, J.G. The role of digestive enzymes in orally induced immune tolerance. *Immunol. Investig.* **1989**, *18*, 1049–1054.
11. Sicherer, S.H.; Muñoz-Furlong, A.; Godbold, J.H.; Sampson, H.A. US prevalence of self-reported peanut, tree nut, and sesame allergy: 11-year follow-up. *J. Allergy Clin. Immunol.* **2010**, *125*, 1322–1326.
12. Untersmayr, E.; Schöll, I.; Swoboda, I.; Beil, W.J.; Förster-Waldl, E.; Walter, F.; Riemer, A.; Kraml, G.; Kinaciyan, T.; Spitzauer, S.; *et al.* Antacid medication inhibits digestion of dietary proteins and causes food allergy: A fish allergy model in BALB/c mice. *J. Allergy Clin. Immunol.* **2003**, *112*, 616–623.
13. Verhasselt, V. Oral tolerance in neonates: From basics to potential prevention of allergic disease. *Mucosal Immunol.* **2010**, *3*, 326–333.
14. Järvinen, K.M.; Konstantinou, G.N.; Pilapil, M.; Arrieta, M.C.; Noone, S.; Sampson, H.A.; Meddings, J.; Nowak-Węgrzyn, A. Intestinal permeability in children with food allergy on specific elimination diets. *Pediatr. Allergy Immunol.* **2013**, *24*, 589–595.

15. Kalach, N.; Rocchiccioli, F.; Boissieu, D.; Benhamou, P.H.; Dupont, C. Intestinal permeability in children: Variation with age and reliability in the diagnosis of cow's milk allergy. *Acta Paediatr.* **2001**, *90*, 499–504.
16. Oyoshi, M.K.; Oettgen, H.C.; Chatila, T.A.; Geha, R.S.; Bryce, P.J. Food allergy: Insights into etiology, prevention, and treatment provided by murine models. *J. Allergy Clin. Immunol.* **2014**, *133*, 309–317.
17. Sanderson, I.R.; Walker, W.A. Uptake and transport of macromolecules by the intestine: Possible role in clinical disorders (an update). *Gastroenterology* **1993**, *104*, 622–639.
18. O'Hagan, D.; Palin, K.; Davis, S. Intestinal absorption of proteins and macromolecules and the immunological response. *Crit. Rev. Ther. Drug Carr. Syst.* **1987**, *4*, 197–220.
19. Hershberg, R.M.; Mayer, L.F. Antigen processing and presentation by intestinal epithelial cells-polarity and complexity. *Immunol. Today* **2000**, *21*, 123–128.
20. Hershberg, R.M.; Cho, D.H.; Youakim, A.; Bradley, M.B.; Lee, J.S.; Framson, P.E.; Nepom, G.T. Highly polarized HLA class II antigen processing and presentation by human intestinal epithelial cells. *J. Clin. Investig.* **1998**, *102*, 792–803.
21. Ziegler, S.F.; Artis, D. Sensing the outside world: TSLP regulates barrier immunity. *Nat. Immunol.* **2010**, *11*, 289–293.
22. Zhu, J.; Paul, W.E. CD4 T cells: Fates, functions, and faults. *Blood* **2008**, *112*, 1557–1569.
23. Mellor, A.L.; Munn, D.H. Physiologic control of the functional status of Foxp3+ regulatory T cells. *J. Immunol.* **2011**, *186*, 4535–4540.
24. Kim, J.S.; Sampson, H.A. Food allergy: A glimpse into the inner workings of gut immunology. *Curr. Opin. Gastroenterol.* **2012**, *28*, 99–103.
25. Iliev, I.D.; Spadoni, I.; Mileti, E.; Matteoli, G.; Sonzogni, A.; Sampietro, G.M.; Foschi, D.; Caprioli, F.; Viale, G.; Rescigno, M. Human intestinal epithelial cells promote the differentiation of tolerogenic dendritic cells. *Gut* **2009**, *58*, 1481–1489.
26. Hadis, U.; Wahl, B.; Schulz, O.; Hardtke-Wolenski, M.; Schippers, A.; Wagner, N.; Müller, W.; Sparwasser, T.; Förster, R.; Pabst, O. Intestinal tolerance requires gut homing and expansion of FoxP3+ regulatory T cells in the lamina propria. *Immunity* **2011**, *34*, 237–246.
27. Kayama, H.; Ueda, Y.; Sawa, Y.; Jeon, S.G.; Ma, J.S.; Okumura, R.; Kubo, A.; Ishii, M.; Okazaki, T.; Murakami, M.; *et al.* Intestinal CX3C chemokine receptor 1high (CX3CR1high) myeloid cells prevent T-cell-dependent colitis. *Proc. Natl. Acad. Sci. USA* **2012**, *109*, 5010–5015.
28. Rescigno, M.; Urbano, M.; Valzasina, B.; Francolini, M.; Rotta, G.; Bonasio, R.; Granucci, F.; Kraehenbuhl, J.P.; Ricciardi-Castagnoli, P. Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. *Nat. Immunol.* **2001**, *2*, 361–367.
29. Niess, J.H.; Brand, S.; Gu, X.; Landsman, L.; Jung, S.; McCormick, B.A.; Vyas, J.M.; Boes, M.; Ploegh, H.L.; Fox, J.G.; *et al.* CX3CR1-mediated dendritic cell access to the intestinal lumen and bacterial clearance. *Science* **2005**, *307*, 254–258.
30. Jang, M.H.; Sougawa, N.; Tanaka, T.; Hirata, T.; Hiroi, T.; Tohya, K.; Guo, Z.; Umemoto, E.; Ebisuno, Y.; Yang, B.G.; *et al.* CCR7 is critically important for migration of dendritic cells in intestinal lamina propria to mesenteric lymph nodes. *J. Immunol.* **2006**, *176*, 803–810.

31. Smit, J.; Bol-Schoenmakers, M.; Hassing, I.; Fiechter, D.; Boon, L.; Bleumink, R.; Pieters, R.H. The role of intestinal dendritic cells subsets in the establishment of food allergy. *Clin. Exp. Allergy* **2011**, *41*, 890–898.
32. Cassani, B.; Villablanca, E.J.; Quintana, F.J.; Love, P.E.; Lacy-Hulbert, A.; Blaner, W.S.; Sparwasser, T.; Snapper, S.B.; Weiner, H.L.; Mora, J.R. Gut-tropic T cells that express integrin $\alpha 4\beta 7$ and CCR9 are required for induction of oral immune tolerance in mice. *Gastroenterology* **2011**, *141*, 2109–2118.
33. Coombes, J.L.; Siddiqui, K.R.; Arancibia-Cárcamo, C.V.; Hall, J.; Sun, C.M.; Belkaid, Y.; Powrie, F. A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF- β and retinoic acid-dependent mechanism. *J. Exp. Med.* **2007**, *204*, 1757–1764.
34. Mucida, D.; Park, Y.; Kim, G.; Turovskaya, O.; Scott, I.; Kronenberg, M.; Cheroutre, H. Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. *Science* **2007**, *317*, 256–260.
35. Schulz, O.; Jaensson, E.; Persson, E.K.; Liu, X.; Worbs, T.; Agace, W.W.; Pabst, O. Intestinal CD103+, but not CX3CR1+, antigen sampling cells migrate in lymph and serve classical dendritic cell functions. *J. Exp. Med.* **2009**, *206*, 3101–3114.
36. Viney, J.L.; Mowat, A.M.; O'Malley, J.M.; Williamson, E.; Fanger, N.A. Expanding dendritic cells *in vivo* enhances the induction of oral tolerance. *J. Immunol.* **1998**, *160*, 5815–5825.
37. Lelouard, H.; Henri, S.; de Bovis, B.; Mugnier, B.; Chollat-Namy, A.; Malissen, B.; Méresse, S.; Gorvel, J.P. Pathogenic bacteria and dead cells are internalized by a unique subset of Peyer's patch dendritic cells that express lysozyme. *Gastroenterology* **2010**, *138*, 173–184.
38. Mucida, D.; Cheroutre, H. TGF β and Retinoic Acid Intersect in Immune-Regulation. *Cell Adhes. Migration* **2007**, *1*, 142–144.
39. Neutra, M.R.; Frey, A.; Kraehenbuhl, J.-P. Epithelial M cells: Gateways for mucosal infection and immunization. *Cell* **1996**, *86*, 345–348.
40. Pabst, O.; Mowat, A. Oral tolerance to food protein. *Mucosal Immunol.* **2012**, *5*, 232–239.
41. Roux, M.E.; McWilliams, M.; Phillips-Quagliata, J.M.; Lamm, M.E. Differentiation pathway of Peyer's patch precursors of IgA plasma cells in the secretory immune system. *Cell. Immunol.* **1981**, *61*, 141–153.
42. Frossard, C.P.; Hauser, C.; Eigenmann, P.A. Antigen-specific secretory IgA antibodies in the gut are decreased in a mouse model of food allergy. *J. Allergy Clin. Immunol.* **2004**, *114*, 377–382.
43. Karlsson, M.; Johansen, F.E.; Kahu, H.; Macpherson, A.; Brandtzaeg, P. Hypersensitivity and oral tolerance in the absence of a secretory immune system. *Allergy* **2010**, *65*, 561–570.
44. Spahn, T.W.; Fontana, A.; Faria, A.; Slavin, A.J.; Eugster, H.P.; Zhang, X.; Koni, P.A.; Ruddle, N.H.; Flavell, R.A.; Rennert, P.D.; *et al.* Induction of oral tolerance to cellular immune responses in the absence of Peyer's patches. *Eur. Immunol.* **2001**, *31*, 1278–1287.
45. Karlsson, M.R.; Rugtveit, J.; Brandtzaeg, P. Allergen-responsive CD4+ CD25+ regulatory T cells in children who have outgrown cow's milk allergy. *J. Exp. Med.* **2004**, *199*, 1679–1688.
46. Qamar, N.; Fishbein, A.B.; Erickson, K.A.; Cai, M.; Szychlinski, C.; Bryce, P.J.; Schleimer, R.P.; Fuleihan, R.L.; Singh, A.M. Naturally Occurring Tolerance Acquisition to Foods in Previously Allergic Children is Characterized by Antigen Specificity and Associated with Increased Subsets of Regulatory T cells. *Clin. Exp. Allergy* **2015**, doi:10.1111/cea.12570.

47. Chatila, T.A.; Blaeser, F.; Ho, N.; Lederman, H.M.; Voulgaropoulos, C.; Helms, C.; Bowcock, A.M. JM2, encoding a fork head-related protein, is mutated in X-linked autoimmunity-allergic dysregulation syndrome. *J. Clin. Investig.* **2000**, *106*, R75–R81.
48. Torgerson, T.R.; Linane, A.; Moes, N.; Anover, S.; Mateo, V.; Rieux-Laucat, F.; Hermine, O.; Vijay, S.; Gambineri, E.; Cerf-Bensussan, N.; *et al.* Severe food allergy as a variant of IPEX syndrome caused by a deletion in a noncoding region of the FOXP3 gene. *Gastroenterology* **2007**, *132*, 1705–1717.
49. Ganeshan, K.; Bryce, P.J. Regulatory T cells enhance mast cell production of IL-6 via surface-bound TGF- β . *J. Immunol.* **2012**, *188*, 594–603.
50. Shevach, E.M. Mechanisms of foxp3⁺ T regulatory cell-mediated suppression. *Immunity* **2009**, *30*, 636–645.
51. Bettini, M.; Vignali, D.A. Regulatory T cells and inhibitory cytokines in autoimmunity. *Curr. Opin. Immunol.* **2009**, *21*, 612–618.
52. Chatila, T.A. Role of regulatory T cells in human diseases. *J. Allergy Clin. Immunol.* **2005**, *116*, 949–959.
53. Lin, W.; Truong, N.; Grossman, W.J.; Haribhai, D.; Williams, C.B.; Wang, J.; Martín, M.G.; Chatila, T.A. Allergic dysregulation and hyperimmunoglobulinemia E in Foxp3 mutant mice. *J. Allergy Clin. Immunol.* **2005**, *116*, 1106–1115.
54. Shreffler, W.G.; Wanich, N.; Moloney, M.; Nowak-Wegrzyn, A.; Sampson, H.A. Association of allergen-specific regulatory T cells with the onset of clinical tolerance to milk protein. *J. Allergy Clin. Immunol.* **2009**, *123*, 43–52.
55. Takahashi, T.; Tagami, T.; Yamazaki, S.; Uede, T.; Shimizu, J.; Sakaguchi, N.; Sakaguchi, S.; Mak, T.W. Immunologic self-tolerance maintained by CD25⁺ CD4⁺ regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. *J. Exp. Med.* **2000**, *192*, 303–310.
56. Sicherer, S.H.; Burks, A.W.; Sampson, H.A. Clinical features of acute allergic reactions to peanut and tree nuts in children. *Pediatrics* **1998**, *102*, e6–e6.
57. Van Asperen, P.; Kemp, A.; Mellis, C. Immediate food hypersensitivity reactions on the first known exposure to the food. *Arch. Dis. Child.* **1983**, *58*, 253–256.
58. Burks, A.W. Peanut allergy. *Lancet* **2008**, *371*, 1538–1546.
59. Du Toit, G.; Roberts, G.; Sayre, P.H.; Bahnson, H.T.; Radulovic, S.; Santos, A.F.; Brough, H.A.; Phippard, D.; Basting, M.; Feeney, M.; *et al.* Randomized trial of peanut consumption in infants at risk for peanut allergy. *N. Engl. J. Med.* **2015**, *372*, 803–813.
60. Frazier, A.L.; Camargo, C.A.; Malspeis, S.; Willett, W.C.; Young, M.C. Prospective study of peripregnancy consumption of peanuts or tree nuts by mothers and the risk of peanut or tree nut allergy in their offspring. *JAMA Pediatr.* **2014**, *168*, 156–162.
61. Greer, F.R.; Sicherer, S.H.; Burks, A.W. Effects of early nutritional interventions on the development of atopic disease in infants and children: The role of maternal dietary restriction, breastfeeding, timing of introduction of complementary foods, and hydrolyzed formulas. *Pediatrics* **2008**, *121*, 183–191.

62. Verhasselt, V.; Milcent, V.; Cazareth, J.; Kanda, A.; Fleury, S.; Dombrowicz, D.; Glaichenhaus, N.; Julia, V. Breast milk-mediated transfer of an antigen induces tolerance and protection from allergic asthma. *Nat. Med.* **2008**, *14*, 170–175.
63. Lack, G.; Fox, D.; Northstone, K.; Golding, J. Factors associated with the development of peanut allergy in childhood. *N. Engl. J. Med.* **2003**, *348*, 977–985.
64. Fox, A.T.; Sasieni, P.; du Toit, G.; Syed, H.; Lack, G. Household peanut consumption as a risk factor for the development of peanut allergy. *J. Allergy Clin. Immunol.* **2009**, *123*, 417–423.
65. Brough, H.A.; Santos, A.F.; Makinson, K.; Penagos, M.; Stephens, A.C.; Douiri, A.; Fox, A.T.; du Toit, G.; Turcanu, V.; Lack, G. Peanut protein in household dust is related to household peanut consumption and is biologically active. *J. Allergy Clin. Immunol.* **2013**, *132*, 630–638.
66. Trendelenburg, V.; Ahrens, B.; Wehrmann, A.K.; Kalb, B.; Niggemann, B.; Beyer, K. Peanut allergen in house dust of eating area and bed—a risk factor for peanut sensitization? *Allergy* **2013**, *68*, 1460–1462.
67. Brough, H.A.; Liu, A.H.; Sicherer, S.; Makinson, K.; Douiri, A.; Brown, S.J.; Stephens, A.C.; Irwin McLean, W.H.; Turcanu, V.; Wood, R.A.; *et al.* Atopic dermatitis increases the effect of exposure to peanut antigen in dust on peanut sensitization and likely peanut allergy. *J. Allergy Clin. Immunol.* **2015**, *135*, 164–170.
68. Brough, H.A.; Simpson, A.; Makinson, K.; Hankinson, J.; Brown, S.; Douiri, A.; Belgrave, D.C.; Penagos, M.; Stephens, A.C.; McLean, W.H.; *et al.* Peanut allergy: Effect of environmental peanut exposure in children with filaggrin loss-of-function mutations. *J. Allergy Clin. Immunol.* **2014**, *134*, 867–875.
69. Chan, S.; Turcanu, V.; Stephens, A.; Fox, A.; Grieve, A.; Lack, G. Cutaneous lymphocyte antigen and $\alpha 4\beta 7$ T-lymphocyte responses are associated with peanut allergy and tolerance in children. *Allergy* **2012**, *67*, 336–342.
70. DeLong, J.H.; Simpson, K.H.; Wambre, E.; James, E.A.; Robinson, D.; Kwok, W.W. Ara h 1-reactive T cells in individuals with peanut allergy. *J. Allergy Clin. Immunol.* **2011**, *127*, 1211–1218.
71. Kubo, A.; Nagao, K.; Amagai, M. Epidermal barrier dysfunction and cutaneous sensitization in atopic diseases. *J. Clin. Investig.* **2012**, *122*, 440–447.
72. Fleckman, P.; Dale, B.A.; Holbrook, K.A. Profilaggrin, a high-molecular-weight precursor of filaggrin in human epidermis and cultured keratinocytes. *J. Investig. Dermatol.* **1985**, *85*, 507–512.
73. Sandilands, A.; Sutherland, C.; Irvine, A.D.; McLean, W.I. Filaggrin in the frontline: Role in skin barrier function and disease. *J. Cell Sci.* **2009**, *122*, 1285–1294.
74. Dale, B.A.; Holbrook, K.A.; Steinert, P.M. Assembly of stratum corneum basic protein and keratin filaments in macrofibrils. *Nature* **1978**, *276* (5689), 729–731.
75. Steinert, P.M.; Cantieri, J.S.; Teller, D.C.; Lonsdale-Eccles, J.D.; Dale, B.A. Characterization of a class of cationic proteins that specifically interact with intermediate filaments. *Proc. Natl. Acad. Sci. USA* **1981**, *78*, 4097–4101.
76. Dale, B.; Resing, K.; Lonsdale-Eccles, J. Filaggrin: A Keratin Filament Associated Protein. *Ann. N. Y. Acad. Sci.* **1985**, *455*, 330–342.

77. Kamata, Y.; Taniguchi, A.; Yamamoto, M.; Nomura, J.; Ishihara, K.; Takahara, H.; Hibino, T.; Takeda, A. Neutral cysteine protease bleomycin hydrolase is essential for the breakdown of deiminated filaggrin into amino acids. *J. Biol. Chem.* **2009**, *284*, 12829–12836.
78. Rawlings, A.; Harding, C. Moisturization and skin barrier function. *Dermatol. Ther.* **2004**, *17*, 43–48.
79. Krien, P.M.; Kermici, M. Evidence for the existence of a self-regulated enzymatic process within the human stratum corneum—an unexpected role for urocanic acid. *J. Investig. Dermatol.* **2000**, *115*, 414–420.
80. Irvine, A.D.; McLean, W.I.; Leung, D.Y. Filaggrin mutations associated with skin and allergic diseases. *N. Engl. J. Med.* **2011**, *365*, 1315–1327.
81. Kezic, S.; Kemperman, P.M.; Koster, E.S.; de Jongh, C.M.; Thio, H.B.; Campbell, L.E.; Irvine, A.D.; McLean, W.H.; Puppels, G.J.; Caspers, P.J. Loss-of-function mutations in the filaggrin gene lead to reduced level of natural moisturizing factor in the stratum corneum. *J. Investig. Dermatol.* **2008**, *128*, 2117–2119.
82. Lambers, H.; Piessens, S.; Bloem, A.; Pronk, H.; Finkel, P. Natural skin surface pH is on average below 5, which is beneficial for its resident flora. *Int. J. Cosmet. Sci.* **2006**, *28*, 359–370.
83. Brattsand, M.; Stefansson, K.; Lundh, C.; Haasum, Y.; Egelrud, T. A proteolytic cascade of kallikreins in the stratum corneum. *J. Investig. Dermatol.* **2005**, *124*, 198–203.
84. Briot, A.; Deraison, C.; Lacroix, M.; Bonnart, C.; Robin, A.; Besson, C.; Dubus, P.; Hovnanian, A. Kallikrein 5 induces atopic dermatitis-like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome. *J. Exp. Med.* **2009**, *206*, 1135–1147.
85. Ovaere, P.; Lippens, S.; Vandenaabeele, P.; Declercq, W. The emerging roles of serine protease cascades in the epidermis. *Trends Biochem. Sci.* **2009**, *34*, 453–463.
86. Miajlovic, H.; Fallon, P.G.; Irvine, A.D.; Foster, T.J. Effect of filaggrin breakdown products on growth of and protein expression by *Staphylococcus aureus*. *J. Allergy Clin. Immunol.* **2010**, *126*, 1184–1190.
87. Roll, A.; Cozzio, A.; Fischer, B.; Schmid-Grendelmeier, P. Microbial colonization and atopic dermatitis. *Curr. Opin. Allergy Clin. Immunol.* **2004**, *4*, 373–378.
88. Cho, S.-H.; Strickland, I.; Tomkinson, A.; Fehringer, A.P.; Gelfand, E.W.; Leung, D.Y. Preferential binding of *Staphylococcus aureus* to skin sites of Th2-mediated inflammation in a murine model. *J. Investig. Dermatol.* **2001**, *116*, 658–663.
89. Fallon, P.G.; Sasaki, T.; Sandilands, A.; Campbell, L.E.; Saunders, S.P.; Mangan, N.E.; Callanan, J.J.; Kawasaki, H.; Shiohama, A.; Kubo, A.; *et al.* A homozygous frameshift mutation in the mouse Flg gene facilitates enhanced percutaneous allergen priming. *Nat. Genet.* **2009**, *41*, 602–608.
90. Sasaki, T.; Shiohama, A.; Kubo, A.; Kawasaki, H.; Ishida-Yamamoto, A.; Yamada, T.; Hachiya, T.; Shimizu, A.; Okano, H.; Kudoh, J.; *et al.* A homozygous nonsense mutation in the gene for Tmem79, a component for the lamellar granule secretory system, produces spontaneous eczema in an experimental model of atopic dermatitis. *J. Allergy Clin. Immunol.* **2013**, *132*, 1111–1120.
91. Saunders, S.P.; Goh, C.S.; Brown, S.J.; Palmer, C.N.; Porter, R.M.; Cole, C.; Campbell, L.E.; Gierlinski, M.; Barton, G.J.; Schneider, G.; *et al.* Tmem79/Matt is the matted mouse gene and is

- a predisposing gene for atopic dermatitis in human subjects. *J. Allergy Clin. Immunol.* **2013**, *132*, 1121–1129.
92. Brown, S.J.; Irvine, A.D. Atopic eczema and the filaggrin story. *Semin. Cutan. Med. Surg.* **2008**, *27* (2), 128–137.
93. Lack, G. Epidemiologic risks for food allergy. *J. Allergy Clin. Immunol.* **2008**, *121*, 1331–1336.
94. Brown, S.J.; Asai, Y.; Cordell, H.J.; Campbell, L.E.; Zhao, Y.; Liao, H.; Northstone, K.; Henderson, J.; Alizadehfar, R.; Ben-Shoshan, M.; *et al.* Loss-of-function variants in the filaggrin gene are a significant risk factor for peanut allergy. *J. Allergy Clin. Immunol.* **2011**, *127*, 661–667.
95. Venkataraman, D.; Soto-Ramírez, N.; Kurukulaaratchy, R.J.; Holloway, J.W.; Karmaus, W.; Ewart, S.L.; Arshad, S.H.; Erlewyn-Lajeunesse, M. Filaggrin loss-of-function mutations are associated with food allergy in childhood and adolescence. *J. Allergy Clin. Immunol.* **2014**, *134*, 876–882.
96. Tan, H.-T.T.; Ellis, J.A.; Koplin, J.J.; Matheson, M.C.; Gurrin, L.C.; Lowe, A.J.; Martin, P.E.; Dang, T.D.; Wake, M.; Tang, M.L.; *et al.* Filaggrin loss-of-function mutations do not predict food allergy over and above the risk of food sensitization among infants. *J. Allergy Clin. Immunol.* **2012**, *130*, 1211–1213.
97. Flohr, C.; England, K.; Radulovic, S.; McLean, W.H.; Campbell, L.E.; Barker, J.; Perkin, M.; Lack, G. Filaggrin loss-of-function mutations are associated with early-onset eczema, eczema severity and transepidermal water loss at 3 months of age. *Br. J. Dermatol.* **2010**, *163*, 1333–1336.
98. Bartnikas, L.M.; Gurish, M.F.; Burton, O.T.; Leisten, S.; Janssen, E.; Oettgen, H.C.; Beaupré, J.; Lewis, C.N.; Austen, K.F.; Schulte, S.; *et al.* Epicutaneous sensitization results in IgE-dependent intestinal mast cell expansion and food-induced anaphylaxis. *J. Allergy Clin. Immunol.* **2013**, *131*, 451–460.
99. Spergel, J.M.; Mizoguchi, E.; Brewer, J.P.; Martin, T.R.; Bhan, A.K.; Geha, R.S. Epicutaneous sensitization with protein antigen induces localized allergic dermatitis and hyperresponsiveness to methacholine after single exposure to aerosolized antigen in mice. *J. Clin. Investig.* **1998**, *101*, 1614–1622.
100. Strid, J.; Hourihane, J.; Kimber, I.; Callard, R.; Strobel, S. Epicutaneous exposure to peanut protein prevents oral tolerance and enhances allergic sensitization. *Clin. Exp. Allergy* **2005**, *35*, 757–766.
101. Birmingham, N.P.; Parvataneni, S.; Hassan, H.; Harkema, J.; Samineni, S.; Navuluri, L.; Kelly, C.J.; Gangur, V. An adjuvant-free mouse model of tree nut allergy using hazelnut as a model tree nut. *Int. Arch. Allergy Immunol.* **2006**, *144*, 203–210.
102. Gonipeta, B.; Parvataneni, S.; Paruchuri, P.; Gangur, V. Long-term characteristics of hazelnut allergy in an adjuvant-free mouse model. *Int. Arch. Allergy Immunol.* **2010**, *152*, 219.
103. Dunkin, D.; Berin, M.C.; Mayer, L. Allergic sensitization can be induced via multiple physiologic routes in an adjuvant-dependent manner. *J. Allergy Clin. Immunol.* **2011**, *128*, 1251–1258.

104. Tordesillas, L.; Goswami, R.; Benedé, S.; Grishina, G.; Dunkin, D.; Järvinen, K.M.; Maleki, S.J.; Sampson, H.A.; Berin, M.C. Skin exposure promotes a Th2-dependent sensitization to peanut allergens. *J. Clin. Investig.* **2014**, *124*, 4965–4975.
105. Soumelis, V.; Reche, P.A.; Kanzler, H.; Yuan, W.; Edward, G.; Homey, B.; Gilliet, M.; Ho, S.; Antonenko, S.; Lauerma, A.; *et al.* Human epithelial cells trigger dendritic cell-mediated allergic inflammation by producing TSLP. *Nat. Immunol.* **2002**, *3*, 673–680.
106. Ebner, S.; Nguyen, V.A.; Forstner, M.; Wang, Y.H.; Wolfram, D.; Liu, Y.J.; Romani, N. Thymic stromal lymphopoietin converts human epidermal Langerhans cells into antigen-presenting cells that induce proallergic T cells. *J. Allergy Clin. Immunol.* **2007**, *119*, 982–990.
107. Ito, T.; Wang, Y.-H.; Duramad, O.; Hori, T.; Delespesse, G.J.; Watanabe, N.; Qin, F.X.; Yao, Z.; Cao, W.; Liu, Y.J. TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand. *J. Exp. Med.* **2005**, *202*, 1213–1223.
108. Yoo, J.; Omori, M.; Gyarmati, D.; Zhou, B.; Aye, T.; Brewer, A.; Comeau, M.R.; Campbell, D.J.; Ziegler, S.F. Spontaneous atopic dermatitis in mice expressing an inducible thymic stromal lymphopoietin transgene specifically in the skin. *J. Exp. Med.* **2005**, *202*, 541–549.
109. Gros, E.; Bussmann, C.; Bieber, T.; Förster, I.; Novak, N. Expression of chemokines and chemokine receptors in lesional and nonlesional upper skin of patients with atopic dermatitis. *J. Allergy Clin. Immunol.* **2009**, *124*, 753–760.
110. Stutte, S.; Quast, T.; Gerbitzki, N.; Savinko, T.; Novak, N.; Reifenberger, J.; Homey, B.; Kolanus, W.; Alenius, H.; Förster, I. Requirement of CCL17 for CCR7- and CXCR4-dependent migration of cutaneous dendritic cells. *Proc. Natl. Acad. Sci. USA* **2010**, *107*, 8736–8741.
111. Stüber, E.; Strober, W. The T cell-B cell interaction via OX40-OX40L is necessary for the T cell-dependent humoral immune response. *J. Exp. Med.* **1996**, *183*, 979–989.
112. Blázquez, A.B.; Berin, M.C. Gastrointestinal dendritic cells promote Th2 skewing via OX40L. *J. Immunol.* **2008**, *180*, 4441–4450.
113. Chu, D.K.; Llop-Guevara, A.; Walker, T.D.; Flader, K.; Goncharova, S.; Boudreau, J.E.; Moore, C.L.; Seunghyun In, T.; Wasserman, S.; Coyle, A.J.; *et al.* IL-33, but not thymic stromal lymphopoietin or IL-25, is central to mite and peanut allergic sensitization. *J. Allergy Clin. Immunol.* **2013**, *131*, 187–200.
114. Imai, Y.; Yasuda, K.; Sakaguchi, Y.; Haneda, T.; Mizutani, H.; Yoshimoto, T.; Nakanishi, K.; Yamanishi, K. Skin-specific expression of IL-33 activates group 2 innate lymphoid cells and elicits atopic dermatitis-like inflammation in mice. *Proc. Natl. Acad. Sci. USA* **2013**, *110*, 13921–13926.
115. Haenuki, Y.; Matsushita, K.; Futatsugi-Yumikura, S.; Ishii, K.J.; Kawagoe, T.; Imoto, Y.; Fujieda, S.; Yasuda, M.; Hisa, Y.; Akira, S.; *et al.* A critical role of IL-33 in experimental allergic rhinitis. *J. Allergy Clin. Immunol.* **2012**, *130*, 184–194.
116. Komai-Koma, M.; Brombacher, F.; Pushparaj, P.; Arendse, B.; McSharry, C.; Alexander, J.; Chaudhuri, R.; Thomson, N.C.; McKenzie, A.N.; McInnes, I.; *et al.* Interleukin-33 amplifies IgE synthesis and triggers mast cell degranulation via interleukin-4 in naïve mice. *Allergy* **2012**, *67*, 1118–1126.

117. Muto, T.; Fukuoka, A.; Kabashima, K.; Ziegler, S.F.; Nakanishi, K.; Matsushita, K.; Yoshimoto, T. The role of basophils and pro-allergic cytokines, TSLP and IL-33, in cutaneously-sensitized food allergy. *Int. Immunol.* **2014**, *26* (10), 539–549.
118. Otsuka, A.; Nakajima, S.; Kubo, M.; Egawa, G.; Honda, T.; Kitoh, A.; Nomura, T.; Hanakawa, S.; Sagita Moniaga, C.; Kim, B.; *et al.* Basophils are required for the induction of Th2 immunity to haptens and peptide antigens. *Nat. Commun.* **2013**, *4*, 1738, doi:10.1038/ncomms2740.
119. Siracusa, M.C.; Saenz, S.A.; Hill, D.A.; Kim, B.S.; Headley, M.B.; Doering, T.A.; Wherry, E.J.; Jessup, H.K.; Siegel, L.A.; Kambayashi, T.; *et al.* TSLP promotes interleukin-3-independent basophil haematopoiesis and type 2 inflammation. *Nature* **2011**, *477*, 229–233.
120. Noti, M.; Kim, B.S.; Siracusa, M.C.; Rak, G.D.; Kubo, M.; Moghaddam, A.E.; Sattentau, Q.A.; Comeau, M.R.; Spergel, J.M.; Artis, D. Exposure to food allergens through inflamed skin promotes intestinal food allergy through the thymic stromal lymphopoietin-basophil axis. *J. Allergy Clin. Immunol.* **2014**, *133*, 1390–1399.
121. Leyva-Castillo, J.M.; Hener, P.; Michea, P.; Karasuyama, H.; Chan, S.; Soumelis, V.; Li, M. Skin thymic stromal lymphopoietin initiates Th2 responses through an orchestrated immune cascade. *Nat. Commun.* **2013**, *4*, doi: 10.1038/ncomms3847.
122. Tang, H.; Cao, W.; Kasturi, S.P.; Ravindran, R.; Nakaya, H.I.; Kundu, K.; Murthy, N.; Kepler, T.B.; Malissen, B.; Pulendran, B. The T helper type 2 response to cysteine proteases requires dendritic cell-basophil cooperation via ROS-mediated signaling. *Nat. Immunol.* **2010**, *11*, 608–617.
123. Burton, O.T.; Darling, A.R.; Zhou, J.S.; Noval-Rivas, M.; Jones, T.G.; Gurish, M.F.; Chatila, T.A.; Oettgen, H.C. Direct effects of IL-4 on mast cells drive their intestinal expansion and increase susceptibility to anaphylaxis in a murine model of food allergy. *Mucosal Immunol.* **2013**, *6*, 740–750.
124. Mathias, C.B.; Hobson, S.A.; Garcia-Lloret, M.; Lawson, G.; Poddighe, D.; Freyschmidt, E.J.; Xing, W.; Gurish, M.F.; Chatila, T.A.; Oettgen, H.C. IgE-mediated systemic anaphylaxis and impaired tolerance to food antigens in mice with enhanced IL-4 receptor signaling. *J. Allergy Clin. Immunol.* **2011**, *127*, 795–805.
125. Lack, G. Update on risk factors for food allergy. *J. Allergy Clin. Immunol.* **2012**, *129*, 1187–1197.
126. Perkin M, L.K.; Craven, J.; Marrs, T.; Radulovic, S.; Flohr, C.; Lack, G.; EAT Study Team. Enquiring About Tolerance (EAT) study—Feasibility of early introduction of allergenic foods and impact on breastfeeding (Oral Presentation). *Clin. Transl. Allergy* **2015**, *5* (Suppl. 3), O6, doi:10.1186/2045-7022-5-S3-O6.
127. Du Toit, G.; Katz, Y.; Sasieni, P.; Mesher, D.; Maleki, S.J.; Fisher, H.R.; Fox, A.T.; Turcanu, V.; Amir, T.; Zadik-Mnuhin, G.; *et al.* Early consumption of peanuts in infancy is associated with a low prevalence of peanut allergy. *J. Allergy Clin. Immunol.* **2008**, *122*, 984–991.
128. Du Toit, G.; Lack, G. Can food allergy be prevented? The current evidence. *Pediatr. Clin. N. Am.* **2011**, *58*, 481–509.
129. Giovannini, M.; D’Auria, E.; Caffarelli, C.; Verduci, E.; Barberi, S.; Indinnimeo, L.; Iacono, I.D.; Martelli, A.; Riva, E.; Bernardini, R. Nutritional management and follow up of

- infants and children with food allergy: Italian Society of Pediatric Nutrition/Italian Society of Pediatric Allergy and Immunology Task Force Position Statement. *Ital. J. Pediatr.* **2014**, *40*, 1, doi:10.1186/1824-7288-40-1.
130. Robbins, K.A.; Guerrerrio, A.L.; Hauck, S.A.; Henry, B.J.; Keet, C.A.; Brereton, N.H.; Oh, S.; Stasinopoulos, D.M.; Wood, R.A. Growth and nutrition in children with food allergy requiring amino acid-based nutritional formulas. *J. Allergy Clin. Immunol.* **2014**, *134*, 1463–1466.
 131. Sicherer, S.H.; Noone, S.A.; Muñoz-Furlong, A. The impact of childhood food allergy on quality of life. *Ann. Allergy Asthma Immunol.* **2001**, *87*, 461–464.
 132. Knibb, R.C.; Hourihane, J.O.B. The psychosocial impact of an activity holiday for young children with severe food allergy: A longitudinal study. *Pediatr. Allergy Immunol.* **2013**, *24*, 368–375.
 133. Nguyen-Luu, N.U.; Ben-Shoshan, M.; Alizadehfar, R.; Joseph, L.; Harada, L.; Allen, M.; Clarke, A.; St-Pierre, Y. Inadvertent exposures in children with peanut allergy. *Pediatr. Allergy Immunol.* **2012**, *23*, 134–140.
 134. Yang, Y.-H.; Chiang, B.-L. Novel approaches to food allergy. *Clin. Rev. Allergy Immunol.* **2014**, *46*, 250–257.
 135. Albin, S.; Nowak-Węgrzyn, A. Potential Treatments for Food Allergy. *Immunol. Allergy Clin. N. Am.* **2015**, *35*, 77–100.
 136. McGowan, E.C.; Wood, R.A. Sublingual (SLIT) Versus Oral Immunotherapy (OIT) for Food Allergy. *Curr. Allergy Asthma Rep.* **2014**, *14*, 1–9.
 137. Chin, S.J.; Vickery, B.P.; Kulis, M.D.; Kim, E.H.; Varshney, P.; Steele, P.; Kamilaris, J.; Hiegel, A.M.; Carlisle, S.K.; Smith, P.B.; *et al.* Sublingual versus oral immunotherapy for peanut-allergic children: A retrospective comparison. *J. Allergy Clin. Immunol.* **2013**, *132*, 476–478.
 138. Keet, C.A.; Frischmeyer-Guerrerio, P.A.; Thyagarajan, A.; Schroeder, J.T.; Hamilton, R.G.; Boden, S.; Steele, P.; Driggers, S.; Burks, A.W.; Wood, R.A. The safety and efficacy of sublingual and oral immunotherapy for milk allergy. *J. Allergy Clin. Immunol.* **2012**, *129*, 448–455.
 139. Thyagarajan, A.; Burks, A.W. Food allergy: Present and future management. *World Allergy Organ. J.* **2009**, *2*, 282–288.
 140. Varshney, P.; Jones, S.M.; Scurlock, A.M.; Perry, T.T.; Kemper, A.; Steele, P.; Hiegel, A.; Kamilaris, J.; Carlisle, S.; Yue, X.; *et al.* A randomized controlled study of peanut oral immunotherapy: Clinical desensitization and modulation of the allergic response. *J. Allergy Clin. Immunol.* **2011**, *127*, 654–660.
 141. Syed, A.; Garcia, M.A.; Lyu, S.-C.; Bucayu, R.; Kohli, A.; Ishida, S.; Berglund, J.P.; Tsai, M.; Maecker, H.; Galli, S.J.; *et al.* Peanut oral immunotherapy results in increased antigen-induced regulatory T-cell function and hypomethylation of forkhead box protein 3 (FOXP3). *J. Allergy Clin. Immunol.* **2014**, *133*, 500–510.
 142. Dupont, C.; Kalach, N.; Soulaines, P.; Legoué-Morillon, S.; Piloquet, H.; Benhamou, P.-H. Cow's milk epicutaneous immunotherapy in children: A pilot trial of safety, acceptability, and impact on allergic reactivity. *J. Allergy Clin. Immunol.* **2010**, *125*, 1165–1167.
 143. Mondoulet, L.; Dioszeghy, V.; Larcher, T.; Ligouis, M.; Dhelft, V.; Puteaux, E.; Cherel, Y.; Letourneur, F.; Dupont, C.; Benhamou, P.H. Epicutaneous immunotherapy (EPIT) blocks the

- allergic esophago-gastro-enteropathy induced by sustained oral exposure to peanuts in sensitized mice. *PLoS ONE* **2012**, *7*, e31967.
144. Mondoulet, L.; Dioszeghy, V.; Ligouis, M.; Dhelft, V.; Dupont, C.; Benhamou, P.H. Epicutaneous immunotherapy on intact skin using a new delivery system in a murine model of allergy. *Clin. Exp. Allergy* **2010**, *40*, 659–667.
145. Mondoulet, L.; Dioszeghy, V.; Vanoirbeek, J.A.; Nemery, B.; Dupont, C.; Benhamou, P.H. Epicutaneous immunotherapy using a new epicutaneous delivery system in mice sensitized to peanuts. *Int. Arch. Allergy Immunol.* **2011**, *154*, 299–309.
146. Dioszeghy, V.; Mondoulet, L.; Dhelft, V.; Ligouis, M.; Puteaux, E.; Benhamou, P.H.; Dupont, C. Epicutaneous immunotherapy results in rapid allergen uptake by dendritic cells through intact skin and downregulates the allergen-specific response in sensitized mice. *J. Immunol.* **2011**, *186*, 5629–5637.
147. Benhamou, P.H.; Dioszeghy, V.; Puteaux, E.; Ligouis, M.; Dhelft, V.; Plaquet, C.; Dupont, C.; Mondoulet, L. Long Term Protection Against New Sensitization After Milk-Epit in Mice Sensitized to Milk Is Mediated by Tregs. *J. Allergy Clin. Immunol.* **2014**, *133*, AB47, doi:10.1016/j.jaci.2013.12.195.
148. Dioszeghy, V.; Mondoulet, L.; Wavrin, S.; Pelletier, B.; Plaquet, C.; Puteaux, E.; Ligouis, M.; Dhelft, V.; Dupont, C.; Benhamou, P.H. Larger and Stronger Expression of Tregs Gut Homing Receptors with Epicutaneous Than with Sublingual or Oral Immunotherapy. *J. Allergy Clin. Immunol.* **2015**, *135*, AB159, doi:10.1016/j.jaci.2014.12.1458.
149. Tordesillas, L.; Mondoulet, L.; Benhamou, P.H.; Sampson, H.A.; Berin, C. Epicutaneous but Not Oral Immunotherapy Induces Antigen-Specific Gastrointestinal Tregs and Protects Against Food-Induced Anaphylaxis. *J. Allergy Clin. Immunol.* **2015**, *135*, AB226, doi:10.1016/j.jaci.2014.12.1674.
150. Senti, G.; Graf, N.; Haug, S.; Rüedi, N.; von Moos, S.; Sonderegger, T.; Johansen, P.; Kündig, T.M. Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy. *J. Allergy Clin. Immunol.* **2009**, *124*, 997–1002.
151. Sheikh, S.Z.; Vickery, B.P.; Steele, P.H.; Kamilaris, J.S.; Michael, D.K., Jr.; Carlisle, S.K.; Christie, G.L.; Jones, S.M.; Burks, A.W. Life with Peanut: Follow up of Tolerant Versus Desensitized Subjects After Peanut OIT. *J. Allergy Clin. Immunol.* **2013**, *131*, AB91, doi:10.1016/j.jaci.2012.12.994.
152. DBV Technologies clinical data (Phase II) (allergy). *Business Insights: Essentials*. 2015, R & D Focus Drug News.
153. Horimukai, K.; Morita, K.; Narita, M.; Kondo, M.; Kitazawa, H.; Nozaki, M.; Shigematsu, Y.; Yoshida, K.; Niizeki, H.; Motomura, K.; *et al.* Application of moisturizer to neonates prevents development of atopic dermatitis. *J. Allergy Clin. Immunol.* **2014**, *134*, 824–830.
154. Simpson, E.L.; Chalmers, J.R.; Hanifin, J.M.; Thomas, K.S.; Cork, M.J.; McLean, W.H.; Brown, S.J.; Chen, Z.; Chen, Y.; Williams, H.C. Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention. *J. Allergy Clin. Immunol.* **2014**, *134*, 818–823.

© 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (<http://creativecommons.org/licenses/by/4.0/>).